These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38004392)

  • 1. Novel Auger-Electron-Emitting
    Obata H; Tsuji AB; Sudo H; Sugyo A; Hashiya K; Ikeda H; Itoh M; Minegishi K; Nagatsu K; Ogawa M; Bando T; Sugiyama H; Zhang MR
    Pharmaceuticals (Basel); 2023 Oct; 16(11):. PubMed ID: 38004392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct Targeting of
    Yoda H; Inoue T; Shinozaki Y; Lin J; Watanabe T; Koshikawa N; Takatori A; Nagase H
    Cancer Res; 2019 Feb; 79(4):830-840. PubMed ID: 30584073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Vitro Evaluation of No-Carrier-Added Radiolabeled Cisplatin ([
    Obata H; Tsuji AB; Sudo H; Sugyo A; Minegishi K; Nagatsu K; Ogawa M; Zhang MR
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33924843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines.
    Aygun N; Altungoz O
    Mol Med Rep; 2019 Jan; 19(1):345-361. PubMed ID: 30483774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thymidylate synthase inhibitor raltitrexed can induce high levels of DNA damage in MYCN-amplified neuroblastoma cells.
    Yamashita K; Kiyonari S; Tsubota S; Kishida S; Sakai R; Kadomatsu K
    Cancer Sci; 2020 Jul; 111(7):2431-2439. PubMed ID: 32415892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour-suppressor microRNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma.
    Buechner J; Tømte E; Haug BH; Henriksen JR; Løkke C; Flægstad T; Einvik C
    Br J Cancer; 2011 Jul; 105(2):296-303. PubMed ID: 21654684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting MYCN IRES in MYCN-amplified neuroblastoma with miR-375 inhibits tumor growth and sensitizes tumor cells to radiation.
    Zhang H; Liu T; Yi S; Gu L; Zhou M
    Mol Oncol; 2015 Aug; 9(7):1301-11. PubMed ID: 25864587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Novel
    Obata H; Tsuji AB; Kumata K; Sudo H; Minegishi K; Nagatsu K; Takakura H; Ogawa M; Kurimasa A; Zhang MR
    J Med Chem; 2022 Apr; 65(7):5690-5700. PubMed ID: 35358392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma.
    Shohet JM; Hicks MJ; Plon SE; Burlingame SM; Stuart S; Chen SY; Brenner MK; Nuchtern JG
    Cancer Res; 2002 Feb; 62(4):1123-8. PubMed ID: 11861392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-localization of the oncogenic transcription factor MYCN and the DNA methyl binding protein MeCP2 at genomic sites in neuroblastoma.
    Murphy DM; Buckley PG; Das S; Watters KM; Bryan K; Stallings RL
    PLoS One; 2011; 6(6):e21436. PubMed ID: 21731748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MRE11 inhibition highlights a replication stress-dependent vulnerability of MYCN-driven tumors.
    Petroni M; Sardina F; Infante P; Bartolazzi A; Locatelli E; Fabretti F; Di Giulio S; Capalbo C; Cardinali B; Coppa A; Tessitore A; Colicchia V; Sahùn Roncero M; Belardinilli F; Di Marcotullio L; Soddu S; Comes Franchini M; Petricci E; Gulino A; Giannini G
    Cell Death Dis; 2018 Aug; 9(9):895. PubMed ID: 30166519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic adenovirus armed with shRNA targeting MYCN gene inhibits neuroblastoma cell proliferation and in vivo xenograft tumor growth.
    Li Y; Zhang B; Zhang H; Zhu X; Feng D; Zhang D; Zhuo B; Li L; Zheng J
    J Cancer Res Clin Oncol; 2013 Jun; 139(6):933-41. PubMed ID: 23443256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma.
    Montemurro L; Raieli S; Angelucci S; Bartolucci D; Amadesi C; Lampis S; Scardovi AL; Venturelli L; Nieddu G; Cerisoli L; Fischer M; Teti G; Falconi M; Pession A; Hrelia P; Tonelli R
    Cancer Res; 2019 Dec; 79(24):6166-6177. PubMed ID: 31615807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inactivation of SMC2 shows a synergistic lethal response in MYCN-amplified neuroblastoma cells.
    Murakami-Tonami Y; Kishida S; Takeuchi I; Katou Y; Maris JM; Ichikawa H; Kondo Y; Sekido Y; Shirahige K; Murakami H; Kadomatsu K
    Cell Cycle; 2014; 13(7):1115-31. PubMed ID: 24553121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDK4 inhibition restores G(1)-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage.
    Gogolin S; Ehemann V; Becker G; Brueckner LM; Dreidax D; Bannert S; Nolte I; Savelyeva L; Bell E; Westermann F
    Cell Cycle; 2013 Apr; 12(7):1091-104. PubMed ID: 23462184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Automatic quantification of gene amplification in clinical samples by IQ-FISH.
    Narath R; Lörch T; Rudas M; Ambros PF
    Cytometry B Clin Cytom; 2004 Jan; 57(1):15-22. PubMed ID: 14696059
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Floros KV; Cai J; Jacob S; Kurupi R; Fairchild CK; Shende M; Coon CM; Powell KM; Belvin BR; Hu B; Puchalapalli M; Ramamoorthy S; Swift K; Lewis JP; Dozmorov MG; Glod J; Koblinski JE; Boikos SA; Faber AC
    Cancer Res; 2021 Apr; 81(7):1896-1908. PubMed ID: 33483374
    [No Abstract]   [Full Text] [Related]  

  • 18. Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells.
    Cetinkaya C; Hultquist A; Su Y; Wu S; Bahram F; Påhlman S; Guzhova I; Larsson LG
    Mol Cancer Ther; 2007 Oct; 6(10):2634-41. PubMed ID: 17938259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and DNA-binding activity of MYCN/Max and Mnt/Max during induced differentiation of human neuroblastoma cells.
    Smith AG; Popov N; Imreh M; Axelson H; Henriksson M
    J Cell Biochem; 2004 Aug; 92(6):1282-95. PubMed ID: 15258910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
    Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
    Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.